| Literature DB >> 30891145 |
Chunjian Liu1, James Lin1, Ryan Moslin1, John S Tokarski1, Jodi Muckelbauer1, ChiehYing Chang1, Jeffrey Tredup1, Dianlin Xie1, Hyunsoo Park1, Peng Li1, Dauh-Rurng Wu1, Joann Strnad1, Adriana Zupa-Fernandez1, Lihong Cheng1, Charu Chaudhry1, Jing Chen1, Cliff Chen1, Huadong Sun1, Paul Elzinga1, Celia D'arienzo1, Kathleen Gillooly1, Tracy L Taylor1, Kim W McIntyre1, Luisa Salter-Cid1, Louis J Lombardo1, Percy H Carter1, Nelly Aranibar1, James R Burke1, David S Weinstein1.
Abstract
In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability. The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramolecular hydrogen bonds. Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNγ production in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.Entities:
Year: 2019 PMID: 30891145 PMCID: PMC6421589 DOI: 10.1021/acsmedchemlett.9b00035
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345